Histidyl-tRNA synthetase-Fc conjugates
US-10093915-B2 · Oct 9, 2018 · US
Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
US10526419B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10526419-B2 |
| Application number | US-201816005045-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 11, 2018 |
| Priority date | Mar 16, 2009 |
| Publication date | Jan 7, 2020 |
| Grant date | Jan 7, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition, comprising a physiologically acceptable carrier and a fusion polypeptide, wherein the fusion polypeptide comprises a histidyl-tRNA synthetase (HRS) polypeptide fused to an Fc fragment, wherein the HRS polypeptide consists of a sequence that has at least 95% identity along its length to SEQ ID NO: 6, comprises a WHEP domain, and lacks a functional aminoacylation domain. 2. The pharmaceutical composition of claim 1 , wherein the HRS polypeptide consists of a sequence that has at least 98% identity along its length to SEQ ID NO: 6. 3. The pharmaceutical composition of claim 1 , wherein the N-terminal region of the HRS reference polypeptide is truncated by 1, 2, or 3 amino acids. 4. A method of treating an inflammatory lung disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of any one of claims 1 - 3 . 5. The method of claim 4 , wherein the lung disease is selected from asthma, autoimmune pulmonary inflammation, and scleroderma. 6. The method of claim 4 , comprising reducing cell migration of monocytes/macrophages in the subject in need thereof. 7. A method of treating an inflammatory granulomatous disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of any one of claims 1 - 3 . 8. A cell-based assay system comprising a cell line that expresses a binding partner of a histidyl-tRNA synthetase (HRS) polypeptide, and a pharmaceutical composition of any one of claims 1 - 3 , wherein the binding partner is cellular protein that associates with the HRS polypeptide. 9. The cell-based assay of claim 8 , wherein the cell line is genetically engineered to express the binding partner. 10. (Previously Presented The cell-based assay of claim 8 , wherein the cell line is selected from COS cells, CHO cells, HEK293 cells, and Hela cells. 11. The cell-based assay of claim 8 , which is adapted for high-throughput screening (HTS).
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunomodulators · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10526419B2 cover?
- Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
- Who is the assignee on this patent?
- Atyr Pharma Inc, Pangu Biopharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/6886. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).